SBSpiros L. Blackburn

Spiros L. Blackburn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Spiros L. Blackburn has a total of 497 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bilateral Versus Unilateral Middle Meningeal Artery Embolization for Unilateral Chronic Subdural Hematoma: A Propensity-Weighted Analysis

    by Bluyé DeMessie, Muhammed Amir Essibayi, Alireza Karandish, Hamza Adel Salim, Deepak Khatri, Neil Haranhalli, Amanda Baker, Richard Zampolin, Allan L. Brook, Seon-Kyu Lee, et al.

    BACKGROUND: Middle meningeal artery embolization (MMAE) is effective for chronic subdural hematoma, but the optimal strategy for unilateral cases is unclear. We compared bilateral versus unilateral MMAE for unilateral chronic subdural hematoma. METHODS: We retrospectively analyzed 526 patients with unilateral chronic subdural hematoma treated with bilateral (n=95) or unilateral (n=431) MMAE. The primary end points were radiographic: the baseline-normalized percentage reduction in SDH thickness and the proportions achieving ≥50% and ≥80% hematoma resolution on follow-up imaging, compared using inverse probability of treatment weighting with 12 covariates including concomitant surgical evacuation. Functional outcomes (modified Rankin Scale score) and safety were secondary. Robustness of the primary findings to center was assessed by leave-one-center-out analysis. RESULTS: After 12-covariate inverse probability of treatment weighting adjustment, bilateral MMAE was associated with more complete radiographic resolution: more patients achieved 50% or greater hematoma reduction (85.9% versus 67.7%; adjusted odds ratio, 2.90 [95% CI, 1.55–5.41]; P P P =0.02) and faster early resolution on a mixed model ( P =0.02). These radiographic findings were not attributable to any single center on leave-one-center-out analysis. Secondary functional outcomes did not differ: good functional outcome (modified Rankin Scale 0–2), 79.8% versus 76.1% (adjusted odds ratio, 1.24 [95% CI, 0.69–2.21]; P =0.46); ordinal modified Rankin Scale shift, common odds ratio, 1.24 (95% CI, 0.80–1.93; P =0.34). CONCLUSIONS: In this inverse probability of treatment weighting–adjusted analysis, bilateral MMAE was associated with more complete and earlier radiographic hematoma resolution than unilateral MMAE, with a similar safety profile; secondary functional outcomes did not differ. These hypothesis-generating findings from an observational cohort require prospective confirmation.

  • Tirofiban Prevents Delayed Cerebral Ischemia After Subarachnoid Hemorrhage in Aged Mice

    by William W. Wroe, Sung‐Ha Hong, Ari Dienel, Kiara Torres, Srilatha Potluri, Peeyush Thankamani Pandit, Richard Cook, Shuning Huang, Sanjana Kavula, Harveen Kaur, et al.

    Background: Microthrombi formation in the cerebral microvasculature has been demonstrated in animal models of subarachnoid hemorrhage (SAH) as well as autopsy studies of patients with aneurysmal SAH, and microthrombi are thought to contribute to delayed cerebral ischemia and poor neurological outcomes. Our hypothesis was that treatment with tirofiban, an antiplatelet drug that inhibits glycoprotein IIb/IIIa, would reduce microthrombi formation and the subsequent sequalae, delayed cerebral ischemia, in aged mice. Methods: SAH was induced via endovascular perforation in male mice, and blood injection in female mice, followed by treatment with either tirofiban or saline. Mice underwent daily neurological assessment for 6 days and then were euthanized. Magnetic resonance imaging scans were obtained on days 2, 4, and 6 after SAH to identify infarcted tissue. Magnetic resonance imaging perfusion and laser speckle contrast imaging were performed to evaluate cerebral perfusion. Postmortem microthrombi formation in the cerebral microvascular was quantified. Results: Tirofiban treatment in male mice, compared with saline, led to reduced microthrombi formation, and prevented delayed infarct growth and neurological decline. In female mice, significant neurobehavioral improvements were observed, which corresponded with fewer brain microthrombi. No female mice had infarction, nor was delayed cerebral ischemia detected in any female mouse. Conclusions: After SAH in mice, treatment with tirofiban reduces both cerebral microthrombi formation and delayed infarct growth leading to a subsequent improvement in neurological outcomes.

  • Machine Learning Prediction of Treatment Failure After Middle Meningeal Artery Embolization for Subdural Hematoma

    by Bluyé DeMessie, Muhammed Amir Essibayi, Hamza Adel Salim, Alireza Karandish, Ahmed Y. Azzam, Deepak Khatri, Neil Haranhalli, Amanda Baker, Richard Zampolin, Allan L. Brook, et al.

    BACKGROUND AND OBJECTIVES: Middle meningeal artery embolization (MMAE) is effective for chronic subdural hematoma (SDH), but failure rates vary and risk prediction tools are lacking. This study developed and validated a machine learning (ML) model to predict MMAE treatment failure for SDH. METHODS: We conducted an international, multi-institutional retrospective cohort study of patients who underwent MMAE for SDH between 2019 and 2025. The cohort was split into training and test sets, stratified by treatment failure, with all hematomas from each patient assigned to a single cohort to prevent data leakage. Multiple ML algorithms were evaluated using 5-fold cross-validation, with gradient boosting selected as the final model. The primary outcome was treatment failure, defined as rescue surgical evacuation or persistent/recurrent SDH requiring retreatment. Model performance was assessed using area under the curve-receiver operating characteristic. Patients were stratified into low-risk (15%) groups using a priori clinically defined thresholds. RESULTS: Among 692 treated hematomas in the test cohort, 64 (9.2%) experienced treatment failure. The gradient boosting model achieved an area under the curve-receiver operating characteristic of 0.856 (95% CI, 0.803-0.902) before calibration and 0.832 (95% CI, 0.766-0.889) after isotonic calibration, with excellent calibration (Brier score, 0.053). The most important predictors were age-platelet interaction, platelet-hemoglobin ratio, platelet count, SDH thickness, and age. Observed treatment failure was 1.6% (95% CI, 0.4%-5.7%) in the low-risk group (n = 124; 17.9%), 6.0% (95% CI, 4.3%-8.4%) in the medium-risk group (n = 516; 74.6%), and 59.6% (95% CI, 46.1%-71.8%) in the high-risk group (n = 52; 7.5%) ( P < .001 for trend), a 37.2-fold difference between high- and low-risk groups. CONCLUSION: This ML model stratified MMAE patients into risk groups with a 37.2-fold difference in treatment failure. High-risk patients had 59.6% failure, whereas low-risk patients had 1.6% failure. Risk stratification may improve patient selection and monitoring.

  • Open Access

    Liquid Embolic Volume Does Not Predict Outcome After Middle Meningeal Artery Embolization for Chronic Subdural Hematoma

    by Abdulrhman Alsalama, Bluyé DeMessie, Muhammed Amir Essibayi, Gaultier Marnat, Hamza Adel Salim, Alireza Karandish, Nimer Adeeb, Dhairya A. Lakhani, Yan-Lin Li, Diego Alejandro Ortega, et al.

    Purpose: Middle meningeal artery embolization (MMAE) is increasingly used for chronic subdural hematoma (CSDH), but the relationship between injected liquid-embolic volume and outcomes is unclear. We evaluated dose–outcome associations and searched for a minimum effective dose. Methods: This retrospective multicenter cohort included 313 patients treated with liquid embolic agents at 12 MESH Registry centers from 2016 to 2024. MMAE was performed alone in 172 patients (55.0%) and adjunctively with surgical evacuation in 141 (45.0%). Dose was assessed as total injected volume per patient and normalized to middle meningeal artery diameter, baseline hematoma thickness, and estimated hematoma volume. The primary outcome was a 180-day composite of retreatment, residual or recurrent hematoma > 10 mm, or death. Logistic regression with multiple imputation, restricted cubic splines, and sensitivity analyses evaluated associations and nonlinearity. Results: Median injected volume was 0.60 mL (interquartile range, 0.50–0.90). Center accounted for 44.5% of variation in log volume, whereas hematoma burden accounted for 0.3%. No dose metric was significantly associated with the primary outcome or 90-day recurrence/reoperation. For absolute volume, the odds ratio per interquartile-range increment was 0.80 (95% confidence interval, 0.56–1.16; p = 0.24). No reliable minimum effective dose was identified. Findings remained consistent across sensitivity analyses and treatment indications (interaction p = 0.30). Procedural complications occurred in 6.4% and were not dose-associated. Conclusion: Within the observed range, injected volume alone was not a consistent determinant of outcome and should not be a procedural target after a satisfactory angiographic endpoint. Future studies should evaluate embolic distribution, distal penetration, and vascular territory coverage.

  • Open Access

    Multi-pedicle versus single-pedicle middle meningeal artery embolization for nonacute subdural hematoma

    by Garrett W Thrash, Bluyé DeMessie, Elijah L Wang, Jesse G Jones, Muhammed Amir Essibayi, Hamza Adel Salim, Alireza Karandish, Deepak Khatri, Neil Haranhalli, Amanda Baker, et al.

    Introduction: Nonacute subdural hematomas (nSDH) are common yet serious extra-axial hemorrhages that result in significant morbidity and mortality. Middle meningeal artery (MMA) embolization (MMAE) is a recent endovascular treatment that involves occlusion of the MMA, inducing hemostasis in and around the hematoma. While many aspects of MMAE have been explored, there is currently limited data on the optimal extent of embolization. Objective: To determine whether single or multiple pedicle embolization of the MMA is superior in inducing hemostasis in nSDH. Methods: We compared single versus multi pedicle embolization by a retrospective multicenter analysis of nSDH patients who underwent MMAE between 2019 and 2024 at participating centers in the MESH (MMA Embolization for Subdural Hematoma) Registry. 679 patients who received a liquid embolic agent with branch-level embolization data were included. Results: While multi-pedicle embolization hastened nSDH thinning at 1 month (5.7 vs. 3.3 mm reduction; difference 2.4 mm, 95% CI 1.0–3.8; P = .002), by 3 months thickness reduction had converged between groups (8.2 vs. 8.4 mm; P = .91). Among 679 patients (456 multi-pedicle, 223 single-pedicle), favorable functional outcome (mRS 0–2) was more frequent with multi-pedicle embolization (53.5% vs. 43.0%; adjusted OR 1.81, 95% CI 1.26–2.60; P = .001), whereas recurrence, rescue surgery, and treatment failure did not differ. Conclusion: Future, multi-center randomized prospective trials are warranted to address confounding variables that limit this observational study. Follow-up beyond 3 months was limited, so durability is unknown.

  • Open Access

    Factors Associated with Short Hospital Stay After Combined Middle Meningeal Artery Embolization and Surgical Evacuation for Chronic Subdural Hematoma

    by Anthony Terraciano, Bluyé DeMessie, Muhammed Amir Essibayi, Abdulrhman Alsalama, Khushal Gupta, Hamza Adel Salim, Alireza Karandish, Nimer Adeeb, Dhairya A. Lakhani, Yan-Lin Li, et al.

    Background: Middle meningeal artery embolization (MMAE) plus surgical evacuation is increasingly used for chronic subdural hematoma (cSDH), but predictors of length of stay (LOS) and outcomes associated with early discharge remain unclear. Methods: We performed a multicenter MESH Registry study (2019–2024) of patients undergoing MMAE and surgical evacuation for symptomatic cSDH. Short-stay discharge was defined as LOS ≤4 days. Predictors were identified using multivariable logistic regression. The 90-day composite adverse event was defined as cSDH recurrence requiring intervention, reintervention (repeat MMAE or surgical evacuation), or 30-day all-cause readmission. Safety was assessed using adjusted logistic regression, generalized estimating equations (GEE), inverse probability of treatment weighting (IPTW), and multiple imputation by chained equations (MICE). Results: Among 647 patients (mean age 72.6 years; 74.0% male), 156 (24.1%) had short-stay discharge. Median LOS was 8 days (IQR 5–15). Older age (aOR 0.76 per 10 years; 95% CI 0.62–0.93; P = 0.008), higher baseline modified Rankin Scale score (aOR 0.79 per point; 95% CI 0.67–0.94; P = 0.007), and greater midline shift (aOR 0.90 per mm; 95% CI 0.85–0.96; P = 0.001) were independently associated with lower odds of short-stay discharge. C‑statistic was 0.683. The 90-day composite event rate was 17.1% in short-stay versus 23.7% in long-stay patients. Short-stay discharge was not significantly associated with the composite outcome on adjusted analysis (aOR 0.56; 95% CI 0.30–1.07; P = 0.08), GEE (aOR 0.61; 95% CI 0.33–1.12; P = 0.11), or MICE (aOR 0.74; 95% CI 0.44–1.25; P = 0.26). IPTW showed a discordant association (OR 0.47; 95% CI 0.24–0.92; P = 0.03). Conclusions: Older age, worse baseline function, and midline shift were associated with longer hospitalization. Short-stay discharge was not associated with a statistically significant increase in adverse-event rates; however, the study was not powered to establish non-inferiority or safety equivalence, and clinically meaningful differences cannot be excluded.


  • Open Access

    Microthrombi and hypercoagulability’s contribution to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

    by William W Wroe, Hussein A Zeineddine, Spiros L Blackburn, Jaroslaw Aronowski, Devin W McBride

    Despite increasing knowledge over the last several decades of the factors contributing to delayed cerebral ischemia (DCI), it remains a significant cause of morbidity after aneurysmal subarachnoid hemorrhage (aSAH). The hypercoagulable state induced by aneurysm rupture is critical to most proposed mechanisms of DCI either through its direct contribution to microthrombi formation, or through the indirect effects of the products of coagulation on vasospasm, and inflammation. In this review we summarize clinical evidence of hypercoagulability after aSAH as well as both the clinical and pre-clinical evidence of its role in DCI, highlighting the role that microthrombi and NETosis are thought to play.


  • Open Access

    Outcomes after flow diversion for ruptured blood blister-like and dissecting aneurysms: A single-center series

    by William W Wroe, Hussein A Zeineddine, Si Y Yu, Bridger H Freeman, Richard S Cook, Charles M Christensen, Peng Roc Chen, Sunil A Sheth, Spiros L Blackburn

    Background: Flow diverter (FD) use has become a popular method for treating intracranial aneurysms, but evidence in acutely ruptured blood blister-like and dissecting morphologies is limited. Furthermore, there is little evidence regarding the role of short-term follow-up imaging to assess aneurysm stability. This study is a single-center retrospective review of dissecting aneurysms treated by FD, with an analysis of short-term follow-up angiograms to guide post-treatment management. Methods: Our single-center retrospective review included all patients from 2016 to 2024 with spontaneous subarachnoid hemorrhage from blood blister-like and dissecting aneurysms who underwent treatment with an FD. Outcomes included re-rupture, treatment failure, re-treatment, aneurysm morphological changes, and ischemic/hemorrhagic events. Short-term, inpatient angiograms were used to assess early response to treatment, and long-term follow-up angiogram, >4 months, was used to assess long-term aneurysm obliteration. Results: Twenty-eight patients underwent FD for treatment of their ruptured dissecting aneurysm. Twelve patients (43%) were treated with coiling plus FD. Treatment failure occurred in four patients (14%). Placement of additional FDs in a second procedure occurred in three patients (11%). Thromboembolic events occurred in five patients (18%). Hemorrhagic complications, not including aneurysm re-rupture, occurred in six patients (21%). Short-term aneurysm improvement occurred in 17 patients (63%). Thirteen patients had long-term follow-up, with 11 (85%) demonstrating complete occlusion. Conclusions: Flow diversion is a reasonable technique for treating ruptured dissecting aneurysms. Risks are moderate and include short-term aneurysm growth and re-rupture. Early post-treatment angiography is suggested to help identify aneurysm growth and the need for re-treatment.


  • Standalone Endovascular Embolization versus Stereotactic Radiosurgery in the Treatment of Arteriovenous Malformations in Eloquent Brain

    by Basel Musmar, Hammam Abdalrazeq, Nimer Adeeb, Hamza Adel Salim, Joanna M. Roy, Assala Aslan, Stavropoula I. Tjoumakaris, Christopher S. Ogilvy, Mustafa K. Baskaya, Douglas Kondziolka, et al.

    Stereotactic radiosurgery was associated with a higher obliteration rate compared with embolization in patients with eloquent brain arteriovenous malformations, whereas there was no evidence of a difference in functional outcomes or complications after adjustment.


  • Open Access

    The role of neutrophils in vasospasm and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: Is it time for a SAH clinical trial targeting neutrophils?

    by William W Wroe, Hussein A Zeineddine, Spiros L Blackburn, Jaroslaw Aronowski, Devin W McBride

    Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating neurological disease, and one of the primary drivers of morbidity after aneurysm rupture is the phenomenon of delayed cerebral ischemia (DCI). Significant knowledge has been gained over the past two decades of the impact of neuroinflammation in DCI; and neutrophils are now believed to play a major role. There is significant human subject data showing the rise of neutrophil related inflammatory markers and neutrophil’s association with poor outcome after aSAH, but as of yet no trials involving human subjects have been done specifically targeting neutrophils. There is however a growing body of evidence in animals models that targeting neutrophils, or their byproducts such as neutrophil extracellular traps improves outcomes. This review summarizes the available evidence of neutrophil’s impact in both human subjects and animal models of aSAH and should serve as an impetuous to explore clinical trials in human subjects.